Focus on the whole process, the first Cancer Management Forum with love set sail.

!-- on August 30, 2020, Takeda China hosted the first "Wu Cai Life, Love Endless" Forum on Cancer Excellence in Shanghai, Chengdu, Guangzhou, Zhengzhou, Nanjing, Hangzhou, Beijing, 7 cities successfully held.
As a cross-disciplinary, multi-dimensional and high-quality academic exchange platform, this forum focuses on breast cancer, prostate cancer, multiple myeloma and lymphoma, bringing together more than 700 experts and scholars from all over the country to discuss the context of the era of treatment of chronic oncology. How to promote its slow-disease management, and to achieve personalized treatment needs of patients, improve treatment limitations as the focus, improve the management model of the whole course of disease, improve the survival and benefit of patients, and ultimately promote the overall development of China's cancer prevention and treatment cause, to help achieve the "Healthy China 2030" action goals.
with the continuous development and progress of medical technology, as well as the consensus of various cancer guidelines on clinical application of the norms and early diagnosis and treatment of the continuous implementation of cancer treatment has become increasingly standardized and mature, into a period of rapid development.
data show that since 2015, The overall five-year survival rate of cancer in China has increased by nearly 10 percentage points compared to 10 years ago;
, it is increasingly important to achieve scientific excellence in disease management around the actual needs of patients clinically.
Professor Zheng Junhua, Professor Ma Jun, Professor Wu Depei, Professor Zhang Jian and Dr. Chen Jie were interviewed during the meeting "with excellence as the goal and management as the core" as the improvement of patients' quality of life, said Professor Wu Depei, Director of the Blood Credit Committee of the Chinese Medical Association.
life expectancy in China is currently about 76 years, according to the "Healthy China 2030" planning outline, by 2030, to further increase the national life expectancy to 79 years.
fact, this is a very big challenge for the medical profession, not only to emphasize "early diagnosis and treatment", but also to continue to move the border forward to strengthen disease prevention.
, however, there are still many shortcomings in China's overall health care that need to be improved.
china is vast and the level of medical care between regions is still very uneven.
In addition, the disease is difficult to achieve standardized management, to blood tumors in the multiple myeloma, for example, because the tumor is more common in elderly patients, improve patient compliance is a major challenge to achieve standardized disease management.
refore, it is very important to carry out graded diagnosis and treatment in our country, explore how to improve the diagnosis and treatment ability of primary health care workers, help patients adhere to the management plan of long-term standardized treatment, and provide better medical security and health care for patients.
With innovation as the trigger point to promote the excellent management of tumor slow disease, Professor Ma Jun, director of Harbin Institute of Hematology Oncology and chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO), pointed out in the interview that the meaning behind "excellent management" is very rich, and the management of cancer patients should be paid attention to.
well known, the incidence of cancer in china has ranked first in the world.
, excellent management for cancer patients should begin by thinking about how to improve patient survival to meet the goal of increasing that number by 15 per cent by 2030.
To lymphoma and multiple myeloma as an example, the current emergence of new treatment methods, facing the future, innovative therapy will become a major trend, in which precision targeted treatment will dominate the treatment of lymphoma, taking into account the efficacy and compliance is the development of multiple myeloma treatment.
Not long ago, China's lymphoma field listed the first antibody association drug (ADC) Vibutoxi monoantigen resistance and in recent years the multi-risk myeloma field of the second-generation oral drug Isazzomi have been quickly approved, this aspect reflects the encouragement of national policy, on the other hand, also reflects the pharmaceutical companies innovation of the internal driving force.
the future, I hope that the "Management Excellence Forum" brand can continue to continue, Takeda will be the field of anti-tumor more innovative products continue to introduce to China, around patients to enhance management excellence, practice corporate value.
The emergence of new drugs has brought positive effects to the improvement of clinical treatment level, and good drugs have always been a powerful "weapon" in the hands of doctors, said Professor Zheng Junhua, vice president of the First People's Hospital affiliated with Shanghai Jiaozhou University and assistant to the Standing Committee and Chairman of the Urology Branch of the Chinese Medical Association.
how to use the "weapons" in their hands is not only a question that the medical community needs to think about now, but also in the future.
In fact, prostate cancer is one of the most suitable cancers for slow disease management, and the current treatment in this area gives clinical confidence, and the next step is to think about how to manage the disease in the long term.
Professor Zheng Junhua said that the "Management Excellence Forum" has given everyone a good opportunity to communicate and learn with doctors in different field of oncology, especially to the medical centers for patient management mechanisms are well worth learning from each other and discussing.
, for example, after learning about fine management of patients in Germany, we have seen that patients' survival time is significantly extended by fine management.
this has given us a good inspiration, in fact, hospitals and enterprises are consistent with the goal of patient-centered, and strive to cure the disease, slow disease management.
"Management Excellence Forum" also reflects the social responsibility of enterprises, for patients to fine management is very much in need of pharmaceutical companies to join, look forward to their joint growth and development with the medical community.
To enhance the concept of disease prevention, increase drug access, adhere to the long-term management of the disease Fudan University affiliated oncology hospital oncology administrative deputy director / first ward medical director, CACA and CSCO breast cancer expert committee member Professor Zhang Jian believes that in the era of precision, cancer patients' diagnosis and treatment management is mainly reflected in the process of evidence-based evidence application and personal experience release, that is, to achieve tailor-made.
but it is not enough to talk about diagnosis and treatment, it is more important to focus on the front end, that is, to strengthen cancer prevention, reduce the prevalence.
look forward to a more comprehensive and chain-wide "forum of excellence" in the future, as well as attention to issues such as prevention, medical policy and drug access, which will make the Forum more distinctive.
In fact, due to the uneven development between regions of our country, in some underdeveloped areas due to differences in concept and drug accessability, the effectiveness of cancer diagnosis and treatment is not significant enough, but through the state, hospitals, enterprises and other aspects to jointly promote the standardized management concept of diseases, as soon as possible to implement the availability of drugs, I believe that the five-year survival rate can be improved.
/!--/ewebeditor:page--!--ewebeditor:page="--for breast cancer, the long-term management of endocrine therapy is a feature of this field.
for hormone-positive patients, endocrine therapy usually reduces the risk of recurrence by 1/3-1/2.
Refore, after the end of complementary chemotherapy, patients are usually advised to take five years of treatment if they need to enter the endocrine treatment phase, and 8-10 years or even lifelong endocrine therapy is recommended for patients at higher risk.
in this context, whether the patient has good compliance, whether to adhere to long-term treatment is very important.
this time, the choice of longer-acting endocrine therapy drugs, reducing the frequency of hospital visits, than short-acting drugs are more conducive to improved patient dependence.
, especially during the new crown outbreak, the advantages of long-acting drugs have been well developed, both to reduce the risk of disease progressity in patients and to reduce the risk of patients being hospitaled.
From the needs of patients, actively lay out the tumor product line, in order to improve the survival rate of cancer patients for 5 years, Dr. Chen Jie, head of The Chinese Medical Affairs Department of Takeda, said that in addition to continuing to tap the potential of classic tumor products, Takeda will continue to make every effort in the field of blood tumors and solid tumors in the next 5-10 years, plans to introduce more than 15 innovative global therapies into China, including a number of cancer treatment drugs, will bring more cancer patients such as non-small cell lung cancer and bone marrow growth syndrome.
In addition, through close cooperation with the academic community, Takeda will help China's clinical continuous production of valuable data, and turn it into practical guiding clinical insights, promote china's guidelines and consensus constantly updated, so that China's academic to the world.
As a global innovative biopharmaceutical company driven by research and development, Takeda will continue to work with all parties to strengthen the construction of excellent cancer management through the platform of the "Management Forum for Excellence" and make unremitting efforts to help achieve the goal of increasing China's overall cancer survival rate by 15% by 2030, as set out in the "Healthy China 2030" strategy.
believe that China's cancer prevention and treatment industry is more expected in the future.
!-- / ewebeditor: page--